Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021
December 27 2021 - 5:10PM
Predictive Oncology
(Nasdaq: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that the Company’s Annual Meeting of Stockholders
was convened at 3:00 p.m. Central Time on December 23, 2021 and was
immediately adjourned due to lack of the required quorum. A quorum
was not achieved because there were fewer than a majority of
outstanding shares entitled to vote, either present in person or
represented by proxy, at the Annual Meeting. The Annual Meeting was
adjourned to 3:00 p.m. Central Time on Thursday, December 30, 2021
at 3300 Wells Fargo Center, 90 South Seventh Street, Minneapolis,
MN 55402 to allow additional time for the Company’s stockholders to
vote on the proposals set forth in the Company’s definitive proxy
statement filed with the Securities and Exchange Commission on
November 5, 2021. During the period of adjournment, the Company
will continue to solicit votes from its stockholders with respect
to the proposals set forth in the proxy statement.
Only stockholders of record as of the record
date, October 26, 2021, are entitled to and are being requested to
vote. At the time the Annual Meeting was adjourned, proxies had
been submitted by stockholders representing approximately 46% of
the shares of the Company’s common stock outstanding and entitled
to vote at the Annual Meeting. Proxies previously submitted in
respect of the Annual Meeting will be voted at the adjourned Annual
Meeting unless properly revoked, and stockholders who have
previously submitted a proxy or otherwise voted need not take any
action.
The Company encourages all stockholders of
record on October 26, 2021 who have not yet voted to do so before
December 29, 2021 at 11:59 p.m., Eastern Time. For additional
information please refer to the proxy statement dated July 7, 2021
available at www.sec.gov and Predictive’s investor relations web
site at http://www.proxypush.com/poai. If you have any questions,
or need assistance in voting, please contact our proxy solicitor
Regan & Associates, Inc., at (212) 587-3005 or
800-737-3426.
About Predictive Oncology
Inc.Predictive Oncology (NASDAQ: POAI) operates through
three segments (Skyline, Helomics and Soluble Biotech), which
contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical
and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins and protein complexes.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024